Nuvectis Pharma, Inc.
NVCTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Nuvectis Pharma, Inc. (NVCT) is listed under Biotechnology. With a market capitalization of $258.6M, it sits in micro-cap territory. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.
Market Cap
$258.6M
Beta
-0.12
P/E (TTM)
—
P/E (Fwd)
-10.16
EPS (TTM)
$-1.31
EPS (Fwd)
$-0.96
ROE
-154.4%
ROA
-63.6%
Cash
$25.1M
Total Debt
$0
Free CF
-$9.2M
52W Change
9.1%
Annual Financials
Cash vs Debt
Nuvectis Pharma, Inc. reports $25.1M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$9.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -154.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The relatively low beta of -0.12 suggests NVCT is a less volatile holding compared to the broader index. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing NVCT's risk profile alongside its fundamentals and technical indicators provides a more complete picture.